212 related articles for article (PubMed ID: 23269235)
1. Inhibition of autophagy enhances sunitinib-induced cytotoxicity in rat pheochromocytoma PC12 cells.
Ikeda T; Ishii KA; Saito Y; Miura M; Otagiri A; Kawakami Y; Shimano H; Hara H; Takekoshi K
J Pharmacol Sci; 2013; 121(1):67-73. PubMed ID: 23269235
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/Akt/mTOR/S6K1 pathways through modulation of Bcl-2 and BAD.
Saito Y; Tanaka Y; Aita Y; Ishii KA; Ikeda T; Isobe K; Kawakami Y; Shimano H; Hara H; Takekoshi K
Am J Physiol Endocrinol Metab; 2012 Mar; 302(6):E615-25. PubMed ID: 21878661
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib inhibits catecholamine synthesis and secretion in pheochromocytoma tumor cells by blocking VEGF receptor 2 via PLC-γ-related pathways.
Aita Y; Ishii KA; Saito Y; Ikeda T; Kawakami Y; Shimano H; Hara H; Takekoshi K
Am J Physiol Endocrinol Metab; 2012 Oct; 303(8):E1006-14. PubMed ID: 22912364
[TBL] [Abstract][Full Text] [Related]
4. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy.
Hosokawa N; Hara T; Kaizuka T; Kishi C; Takamura A; Miura Y; Iemura S; Natsume T; Takehana K; Yamada N; Guan JL; Oshiro N; Mizushima N
Mol Biol Cell; 2009 Apr; 20(7):1981-91. PubMed ID: 19211835
[TBL] [Abstract][Full Text] [Related]
5. mTORC1 phosphorylates the ULK1-mAtg13-FIP200 autophagy regulatory complex.
Chan EY
Sci Signal; 2009 Aug; 2(84):pe51. PubMed ID: 19690328
[TBL] [Abstract][Full Text] [Related]
6. Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
Denorme M; Yon L; Roux C; Gonzalez BJ; Baudin E; Anouar Y; Dubessy C
Cancer Lett; 2014 Oct; 352(2):236-44. PubMed ID: 25016061
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.
Cassol CA; Winer D; Liu W; Guo M; Ezzat S; Asa SL
Mod Pathol; 2014 Aug; 27(8):1050-62. PubMed ID: 24390213
[TBL] [Abstract][Full Text] [Related]
8. Interferon alpha and rapamycin inhibit the growth of pheochromocytoma PC12 line in vitro.
Motylewska E; Lawnicka H; Kowalewicz-Kulbat M; Sicinska P; Niedziela A; Melen-Mucha G; Stepien H
Endokrynol Pol; 2013; 64(5):368-74. PubMed ID: 24186594
[TBL] [Abstract][Full Text] [Related]
9. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
10. [Sunitinib induces autophagy via suppressing Akt/mTOR pathway in renal cell carcinoma].
Cao P; Jiang XJ; Xi ZJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):584-589. PubMed ID: 29263493
[TBL] [Abstract][Full Text] [Related]
11. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery.
Jung CH; Jun CB; Ro SH; Kim YM; Otto NM; Cao J; Kundu M; Kim DH
Mol Biol Cell; 2009 Apr; 20(7):1992-2003. PubMed ID: 19225151
[TBL] [Abstract][Full Text] [Related]
12. Atg13 and FIP200 act independently of Ulk1 and Ulk2 in autophagy induction.
Alers S; Löffler AS; Paasch F; Dieterle AM; Keppeler H; Lauber K; Campbell DG; Fehrenbacher B; Schaller M; Wesselborg S; Stork B
Autophagy; 2011 Dec; 7(12):1423-33. PubMed ID: 22024743
[TBL] [Abstract][Full Text] [Related]
13. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.
Zhang X; Wang X; Qin L; Xu T; Zhu Z; Zhong S; Zhang M; Shen Z
Urology; 2015 Jan; 85(1):273.e1-7. PubMed ID: 25440763
[TBL] [Abstract][Full Text] [Related]
14. ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy.
Ganley IG; Lam du H; Wang J; Ding X; Chen S; Jiang X
J Biol Chem; 2009 May; 284(18):12297-305. PubMed ID: 19258318
[TBL] [Abstract][Full Text] [Related]
15. The ULK1 complex mediates MTORC1 signaling to the autophagy initiation machinery via binding and phosphorylating ATG14.
Park JM; Jung CH; Seo M; Otto NM; Grunwald D; Kim KH; Moriarity B; Kim YM; Starker C; Nho RS; Voytas D; Kim DH
Autophagy; 2016; 12(3):547-64. PubMed ID: 27046250
[TBL] [Abstract][Full Text] [Related]
16. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
[TBL] [Abstract][Full Text] [Related]
17. Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer.
Li X; Tong LJ; Ding J; Meng LH
Cancer Lett; 2014 Jan; 342(1):159-66. PubMed ID: 24018642
[TBL] [Abstract][Full Text] [Related]
18. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling.
Ikezoe T; Nishioka C; Tasaka T; Yang Y; Komatsu N; Togitani K; Koeffler HP; Taguchi H
Mol Cancer Ther; 2006 Oct; 5(10):2522-30. PubMed ID: 17041096
[TBL] [Abstract][Full Text] [Related]
19. PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway.
Zhang X; Zhong S
Anticancer Agents Med Chem; 2020; 20(7):828-833. PubMed ID: 32188393
[TBL] [Abstract][Full Text] [Related]
20. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
